WIN Consortium and Pfizer Collaborate to Advance Personalized Cancer Care

Posted: Monday, December 10, 2012


VILLEJUIF, France-(BUSINESS WIRE)

The Worldwide Innovative Network (WIN) in personalized cancer medicine consortium today proudly announced that Pfizer, Inc (NYSE:PFE) is the first pharmaceutical company to become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide.

Pfizer’s strong corporate commitment to the development of drugs using a precision medicine approach, coupled with the company’s deep breadth of experience in the development of oncology therapeutics, strategically align the company’s goals and capabilities with the mission of the WIN Consortium. As the newest member of the consortium, Pfizer will play an integral role in shaping the future achievements of this collective group on behalf of cancer patients around the world.


About the WIN Consortium

Initiated in 2010 by the University of Texas MD Anderson Cancer Center (USA) and the Institut Gustave Roussy (France), the WIN Consortium is a global network of 25 leading organizations from the academic, pharmaceutical, biotechnology, healthcare IT, and patient advocacy sectors working to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN is a non-governmental, not-for-profit organization headquartered in Paris.


Contacts

Catherine Bresson:
Director Operational Team
Catherine.bresson@winconsortium.org